NCT02128906 2026-04-16
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
10 trialsNCT04590963 2026-03-13
INTERLINK-1
AstraZeneca
Phase 3 Active not recruiting
NCT01884259 2022-05-26
HNO-2
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT01326923 2020-10-09
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 2 Terminated
NCT02236936 2020-05-01
AGMT_HNO_PN
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 3 Terminated
NCT02205398 2019-01-22
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Novartis
Phase 1 Terminated
NCT01540682 2018-08-29
MLN8237 in Head and Neck Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01087970 2014-05-19
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01057589 2013-09-18
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01427205 2013-04-05
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn